Phillip P. Chan - 12 Jun 2026 Form 4 Insider Report for Cytosorbents Corp (CTSO)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: CTSO
Reported as of: 12 Jun 2026
Net transaction value: +$104,898
SEC form: 4
Accepted by SEC: 15 Jun 2026, 18:24:29 UTC
Prior SEC filing: 20 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/ Phillip P. Chan

Key filing fact

Phillip P. Chan filed Form 4 for Cytosorbents Corp (CTSO) on 15 Jun 2026.

Key facts

This page summarizes Phillip P. Chan's Form 4 filing for Cytosorbents Corp (CTSO).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 15 Jun 2026, 18:24.

Change

Previous filing in this sequence was filed on 20 Nov 2025.
Current net transaction value: +$104,898.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001442786 Primary reporting owner

Chan Phillip P.

Relationship: Chief Executive Officer, Director
Address: C/O CYTOSORBENTS CORPORATION, 305 COLLEGE ROAD EAST, PRINCETON
Signature: /s/ Phillip P. Chan
Signature date: 15 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CTSO transaction

Common Stock

Purchase

Transaction value: $100,454
Shares: +251,136
Change %: +17%
Price: $0.4000
Shares after: 1,734,099
Date: 12 Jun 2026
Ownership: Direct
Footnotes: F1, F2, F3

CTSO transaction

Common Stock

Purchase

Transaction value: $4,443
Shares: +10,333
Change %: +0.6%
Price: $0.4300
Shares after: 1,744,432
Date: 15 Jun 2026
Ownership: Direct
Footnotes: F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The transaction reported on this Form 4 reflects an open market purchase made by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.3885 to $0.40, inclusive. The Reporting Person undertakes to provide to CytoSorbents Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (4) to this Form 4.

Footnote F2

Includes: (i) the following restricted stock units ("RSUs") that will be settled into shares of Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015;

Footnote F3

(continued from footnote 2) (iii) 105,600 RSUs granted on August 8, 2025, which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and (iv) 1,422,832 shares of Common Stock owned by the Reporting Person.

Footnote F4

The transaction reported on this Form 4 reflects an open market purchase made by the reporting person. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.4307 to $0.4388, inclusive.